Watch and wait after immunotherapy for locally recurrent nasopharyngeal cancer
Part of Cancer, Ear, nose & throat, Mouth & dental clinical trials.
This study tests whether pausing cancer treatment after initial immunotherapy can be safe for people with nasopharyngeal cancer that has returned only in the head and neck area. The goal is to avoid unnecessary extra treatment if the cancer is well controlled.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You must have newly diagnosed nasopharyngeal cancer that has not been treated before and has spread only in the head and neck area (not to other parts of the body).
- You must be scheduled to receive or already receiving immunotherapy (a type of treatment that helps your immune system fight cancer).
- You must have at least one measurable tumor, as seen on scans.
- You must have adequate organ function and be able to give informed consent.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at whether adding chemo-immunotherapy after surgery is better than surgery alone for patients whose nasopharyngeal cancer has returned but is still in early stages. It may help prevent the cancer from coming back again.
This trial studies toripalimab (an immunotherapy that helps your immune system attack cancer) for nasopharyngeal cancer that has come back locally. It may help shrink or control the returning tumor and improve outcomes for people who meet the safety and lab requirements.
This trial compares giving chemotherapy and immunotherapy before surgery (neoadjuvant) versus after surgery (adjuvant) for patients whose nasopharyngeal cancer has returned locally. It aims to find which approach works better to control the cancer.
This trial tests a combination of chemotherapy and immunotherapy (pembrolizumab) given before and after surgery for nasopharyngeal cancer that has come back locally. The goal is to see if this approach can control the cancer and improve outcomes for patients who can't have standard re-treatment.
This trial tests whether maintenance immunotherapy (PD-1 inhibitor) followed by delayed salvage radiation therapy can help keep your cancer under control after you have already responded to initial chemo-immunotherapy. It is for people with recurrent nasopharyngeal carcinoma that has come back in the nose or neck area, but has not spread to distant organs.
This trial studies whether adding an anti–PD-1 immunotherapy to standard chemoradiotherapy can control nasopharyngeal cancer that has come back in the local area. It may help patients live longer or have the cancer respond better compared with chemoradiotherapy alone.
Hear when a new Recurrent Nasopharyngeal Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.